Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2025-12-24 @ 11:39 PM
NCT ID:
NCT00473551
Eligibility Criteria:
Inclusion Criteria:
* Age 18-70
* Confirmed diagnosis of follicular lymphoma, mantle cell lymphoma, chronic lymphocyte leukemia/small lymphocytic lymphoma or multiple myeloma. Patients must have had persistent or progressive disease despite initial chemotherapy. Patients must have achieved a partial or complete response to their most recent chemotherapy.
* Patients must have an human leukocyte antigen (HLA) matched (HLA-A, B, C DR or DQ) related donor who is seropositive against Epstein Barr virus and capable of donating peripheral blood mononuclear cells and peripheral blood progenitor cells.
* Patient must be HLA completely mismatched for HLA class I loci (A, B and C) with the 3rd party stimulator cells. HLA-A (330301, 310102) HLA-B (5801,150101\[62\]) HLA-C (0302, 030301)
* Zubrod Performance Scale (PS) of 0 or 1
* Creatinine \< 1.8 mg/dl
* Ejection fraction \>/=40%
* Corrected Carbon Monoxide Diffusing Capacity (DLCO) \>/=45% predicted
* Serum bilirubin \</=1.5 mg/dl if not due to Gilbert's syndrome
Exclusion Criteria:
* Uncontrolled infection
* HIV, hepatitis B surface antigen or hepatitis C seropositive
* serum glutamic-pyruvic transaminase (SGPT) \> 200 IU/ml
* Pregnant or lactating women i.e., positive Beta human chorionic gonadotrophin (hCG) test in a woman with child bearing potential. Child bearing potential is defined as not post-menopausal for 12 months or no previous surgical sterilization.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT00473551
Study Brief:
Protocol Section:
NCT00473551